Nureca Limited has submitted its quarterly regulatory certificate to both BSE and NSE, fulfilling compliance requirements under SEBI regulations for the quarter ended March 31, 2026. The filing demonstrates the company's adherence to mandatory reporting obligations regarding its shareholding structure.

Regulatory Compliance Filing

The certificate was filed pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. Company Secretary and Compliance Officer Nishu Kansal signed the submission on April 15, 2026, ensuring timely compliance with regulatory deadlines.

Shareholding Structure Confirmation

Alankit Assignments Limited, serving as the company's Registrar and Share Transfer Agent, provided the certificate confirming the shareholding status. The RTA's communication, signed by Manager Ramesh Khatau, contained specific details about the company's shareholder base during the reporting period.

Stock Exchange Submissions

The certificate was simultaneously submitted to both major Indian stock exchanges where Nureca's shares are listed. The company maintains its listing presence on both platforms, ensuring comprehensive regulatory compliance across all trading venues.

The BSE submission referenced scrip code 543264, while the NSE filing used scrip code NURECA. Both exchanges received identical documentation confirming the company's shareholding structure and compliance status for the quarter.

Corporate Information

Nureca Limited operates from its correspondence office in Chandigarh and registered office in Mumbai. The company maintains its corporate identification number L24304MH2016PLC320868 and continues its partnership with Alankit Assignments Limited for registrar and share transfer services.

This quarterly filing represents part of Nureca's ongoing regulatory obligations, ensuring transparency in its shareholding structure and maintaining compliance with SEBI's depositories and participants regulations.

Nureca Limited has filed a disclosure under Regulation 10(6) of SEBI Takeover Regulations dated January 27, 2026, reporting an increase in promoter group shareholding following the completion of its share buyback program. The company's promoter group shareholding has risen from 64.97% to 68.09% due to the extinguishment of shares purchased during the buyback.

Share Buyback Impact on Ownership Structure

The change in shareholding percentage resulted from the company's share buyback program that opened on December 18, 2025, and closed on December 24, 2025. The shares were subsequently extinguished on January 07, 2026. Importantly, the promoter group did not acquire any additional shares during this process - their percentage increase stems from the reduction in total share capital following the buyback.

Promoter Group Composition and Holdings

The promoter group consists of five entities, with Saurabh Goyal holding the largest stake. The individual shareholding details show how each member's percentage increased proportionally due to the reduced share capital.

Regulatory Compliance and Exemptions

The disclosure was made under Regulation 10(6) of the SEBI Takeover Regulations, with the promoter group claiming exemption under Regulation 10(4)(c). This exemption applies when the increase in shareholding percentage results from a buyback rather than fresh acquisition of shares. The company confirmed that no prior intimation under Regulation 10(5) was required as the transaction qualified for the specified exemption.

Corporate Structure Details

Nureca Limited is listed on both BSE Limited (scrip code: 532649) and National Stock Exchange of India Limited (scrip: NECLIFE). The disclosure was signed by all promoter group members on January 27, 2026, from Chandigarh, with Saurabh Goyal also signing on behalf of Nectar Biopharma Private Limited in his capacity as Director (DIN: 00136037).